Clinical Lid Eradication of Antifungal-Responsive FUNGUS Study

Conditions

• Anterior Blepharitis

Eligibility Criteria

Sex

ALL

Age

18 Years - N/A

Healthy Volunteers

Not accepted

Interventions

• NATACYN® — DRUG
  Natamycin 5% ophthalmic suspension (Natacyn®) is FDA-approved for the treatment of fungal blepharitis, conjunctivitis, and keratitis caused by susceptible organisms (NATACYN US Prescribing Information). The route of administration in this study - application to the eye at a frequency of QID for 21 days - is consistent with the labeled dosing range for fungal blepharitis (one drop, 4 to 6 times daily).

Study Details

The goal of this clinical trial is to learn if Natacyn works to reduce or eliminate laboratory-confirmed fungal organisms in subjects with fungal-positive blepharitis identified in a previous study. asthma in adults. It will also learn more about the safety of Natacyn. The main questions it aims to answer are: Does Natacyn reduce or eliminate fungal presence? Does Natacyn cause a reduction in eye irritation and itchiness? What medical problems do participants have when using Natacyn? Participants will: Apply Natacyn 4 times a day for 21 days Visit the clinic once every week for checkups and tests Keep a diary of the number of times they apply Natacyn over the 21-day period

Key Dates

First listed

Oct 2, 2026

Start date

Oct 31, 2026

Status verified

Sep 2026

Primary completion

Mar 31, 2027

Completion

Mar 31, 2027

Study Design

Enrollment

60 participants (estimated)

Allocation

NA

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Arms

• Experimental: CLEAR - Clinical Lid Eradication of Antifungal-Responsive FUNGUS Study
  Natacyn (natamycin ophthalmic suspension 5%) applied to affected eye 4 times a day (QID) for 21 days

Primary Outcome Measure

Change from baseline in VAS irritation, VAS itching, and VFQ25 from baseline to Day 21 [ Time Frame: From enrollment to the end of treatment at 21 days ]

Locations (5)

Find similar trials in Jacksonville, FL

Related Studies

• Ocular Dysbiosis in Eyelid Disease
  Recruiting · Brent Kramer · Jacksonville, Florida